FMP
Immix Biopharma, Inc.
IMMX
NASDAQ
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
2.17 USD
-0.05 (-2.3%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.immixbio.comexchange
NASDAQ
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorpor...
CIK
0001873835
ISIN
US45258H1068
CUSIP
45258H106
Address
11400 West Olympic Boulevard
Phone
310 651 8041
Country
US
Employee
14
IPO Date
Dec 16, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
IMMX Financial Summary
CIK
0001873835
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45258H106
ISIN
US45258H1068
Country
US
Price
2.17
Beta
0.1
Volume Avg.
177.53k
Market Cap
59.69M
Shares
-
52-Week
1.26-7.5
DCF
1.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.58
P/B
-
Website
https://www.immixbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMMX News
It looks like there's no news available.
